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 Abstract: 
The article examines the role and challenges of scientific self-governance and 
standardization in inter-continental clinical research partnerships in stem cell 
medicine. The paper shows that – due to a high level of regulatory diversity – the 
enactment of internationally recognized standards in multi-country stem cell trials is a 
complex and highly situation-specific achievement. Standardization is imposed on a 
background of regulatory, institutional and epistemic-cultural heterogeneity, and 
implemented exclusively in the context of select clinical projects. Based on 
ethnographic data from the first trans-continental clinical trial infrastructure in stem 
cell medicine between China and the USA, the article demonstrates that locally 
evolved and international forms of experimental clinical research practices often co-
exist in the same medical institutions. Researchers switch back and forth between 
these schemas, depending on the purposes of their research, the partners they work 
with, the geographic scale of research projects, and the contrasting demands for 
regulatory review, that result from these differences. Drawing on Birch’s analysis of 
the role of standardization in international forms of capital production in the 
biosciences, the article argues that the integration of local knowledge institutions into 
the global bioeconomy does not necessarily result in the shutting down of localized 
forms of value production. In emerging fields of medical research, that are regulated 
in highly divergent ways across geographical regions, the coexistence of distinct 
modes of clinical translation allows also for the production of multiple forms of 
economic value, at varying spatial scales. This is especially so in countries with 
lenient regulations. As this paper shows, the long-standing absence of a regulatory 
framework for clinical stem cell applications in China, permits the situation-specific 
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adoption of internationally recognized standards in some contexts, while enabling the 
continuation of localized forms of value production in others.  
 
 
Key-terms: China, regenerative stem cell medicine, clinical trials, situational 
standardization, scientific self-governance, research regulation, international 
collaborations 
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Introduction  
 
In this article, I focus on processes of scientific self-governance and standardization in 
the context of intercontinental clinical research collaborations in the field of 
regenerative stem cell medicine. I will explore, furthermore, the implications of these 
processes on local clinical innovation practices, and the production of localized forms 
of economic value. The paper explores these issues by focusing on the formation of 
the China Spinal Cord Injury Network (China SCI Net), the first intercontinental 
clinical trials infrastructure in the stem cell field that has emerged between medical 
researchers in mainland China, Hong Kong, Taiwan and the USA.  
The emergence of a global clinical trial landscape has been a key theme in the 
literature on industry-sponsored forms of clinical research on vaccines and drugs 
based on chemical compounds (Leach et al., 1999; Gikonyo, Bejon, Marsh, & 
Molyneux, 2008; Petryna 2009; Sariola, & Simpson, 2011). To date, however, no 
study has systematically focused on the formation of international clinical trials in the 
field of regenerative stem cell medicine. Existing academic work on the clinical 
translation of stem cell-based therapeutic approaches has focused either on processes 
of preclinical development (Cribb, et al., 2008; Martin, Brown and Kraft, 2008; 
Wainwright, et al., 2006), or on clinical research in the context of national 
jurisdictions, especially in the USA and in countries of the European Union (Wilson-
Kovacs, Weber, & Hauskeller 2010; Webster, Haddad, & Waldby, 2011). A third 
body of work has been concerned with the provision of experimental for-profit 
interventions with stem cells, outside of the methodological format of the clinical 
trial. These studies have commented in particular on the situation in China (Song, 
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2011; Chen, & Gottweis, 2011; Rosemann, 2013a) and India (Bharadwaj, 2013; 
Sleeboom-Faulkner, & Patra 2011).  
The development of regenerative stem cell medicine through internationally 
acknowledged multi-country clinical trial partnerships has remained unexplored so 
far. This is an important analytical shortcoming. A focus on the formation of 
international clinical trial infrastructures provides important opportunities to gain 
insights into the processes and challenges involved in the development, organization, 
and governance of large-scale, transcontinental clinical research collaborations in the 
field of regenerative stem cell medicine (as well as other emerging fields of medicine 
research). Of particular interest, in this respect, are processes of standardization, 
which in recent years have evolved as important concerns in the social study of 
medicine research (Timmermans, & Berg, 1997; Timmermans, & Epstein, 2010; 
Birch, 2012). The evolving field of clinical stem cell medicine forms an interesting 
case in this respect. In contrast to established forms of drug research, for clinical stem 
cell research there are as yet no internationally binding standards or harmonized 
global governance frameworks, and widely divergent regulatory conditions exist 
across (and within) countries. The governments of the USA, the European Union and 
some other countries have now developed legal arrangements for the licensing of 
stem cell-based medicinal products (Halme, & Kessler, 2006; Faulkner, 2012). In 
many other countries, however, including in population rich countries such as China 
and India – where unproven for-profit applications with stem cells constitute a huge 
market – the development of regulatory frameworks is evolving only gradually 
(Sleeboom-Faulkner, & Patra, 2011; Rosemann, 2013a). In China, the experimental 
clinical use of stem cells remained completely unregulated until January 2012, with 
the result that highly dissimilar types of clinical research and experimental for-profit 
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applications have surfaced since the early 2000s (Chen, 2009; Song, 2011; Rosemann, 
2013a).  
The argument in this paper is developed in two parts. First, I will show that the 
high level of regulatory diversity in the international landscape of clinical stem cell 
research, poses a significant challenge to the organization of cross-continental clinical 
trial collaborations. By focusing on the formation of the China Spinal Cord Injury 
Network (China SCI Net), the first trans-continental clinical trial infrastructure in 
stem cell medicine between China and the USA, the article will elucidate that the 
enactment of internationally recognized clinical research standards is a complex and 
highly situation-specific achievement. Standardization, as will be shown, relies on 
extensive forms of scientific self-governance, and requires far-reaching adjustments 
of local clinical research environments. Internationally approved methodological 
protocols are established against a background of regulatory, institutional and 
epistemic-cultural heterogeneity, and implemented in the situational context of the 
clinical trials organized by the China SCI Net. Exterior to the activities of the China 
SCI Net, we see that locally evolved and newly adopted (i.e. internationally accepted) 
forms of experimental clinical research practices exist side by side with each other, 
often in the same medical institutions. Researchers shift between these divergent 
schemas, depending on the purposes of their research, the partners they work with, the 
geographic scale of research projects, and the contrasting demands for regulatory 
review, that result from these differences. Second, based on these insights I will 
engage in a dialogue with a recent analysis of the role of standardization in the 
creation of value in the biosciences by sociologist Kean Birch (2012). I will argue that 
– in the regenerative medicine field – the integration of local knowledge institutions 
into the global bioeconomy does not necessarily result in the shutting down of 
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localized forms of value production. While the blocking of local forms of capital 
production in the biomedical sciences can be observed in particular in established 
fields of medical research, and in countries with stringent regulatory controls in place, 
in emerging fields of medicine research, a more diversified situation exists. In 
emerging socio-technical fields of medical research, such as regenerative stem cell 
medicine, which is regulated in highly divergent ways across (and often within) 
geographical regions, the close proximity between locally evolved and internationally 
recognized forms of clinical translation allows also for the production of multiple 
forms of economic and scientific value. Localized forms of value creation in medical 
institutions, that do not conform to the requirements of international scientific 
standard regimens, continue to exist – aside to participation in internationally 
approved, multi-country clinical research projects. Geographic location, and 
regulatory differences between these locations, is a key factor in explaining this 
situation. As this paper shows, the long-standing absence of a comprehensive 
regulatory framework for clinical stem cell applications in China permits the 
situation-specific adoption of internationally recognized standards in some contexts, 
while enabling the continuation of local forms of value production in others.  
 
 
Empirical context and methodology 
 
The empirical focal point of this article is an ethnographic study of the China Spinal 
Cord Injury Network (China SCI Net), an academic clinical trials infrastructure that 
involves more than twenty spinal cord injury (SCI) centers in mainland China, Hong 
Kong, and Taiwan. The Network is registered as a non-profit corporation in Hong 
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Kong, and was founded in 2005 by Professor Wise Young from Rutgers University in 
New Jersey, in close collaboration with leading researchers from Hong Kong and the 
Chinese mainland (Rosemann, 2013b). Since 2009, the China SCI Net has been 
paralleled by the Spinal Cord Injury Network USA (SCI Net USA), which comprises 
eight academic hospitals. The aim of this evolving transnational research economy is 
to develop and clinically assess stem cell-based combination therapies for spinal cord 
injury, and the licensing of successfully tested treatments in China, Hong Kong, 
Taiwan, the USA, and potentially other countries in the world. Until April 2014, the 
China SCI Net had conducted seven clinical studies. An initial noninterventional 
observational study was carried out between 2005 and 2008 in twenty-two hospitals 
to collect diagnostic and long-term follow-up data from up to 600 acute and chronic 
SCI patients. This study was followed by five phase I and II trials that have been 
conducted in chronic SCI patients, in two university hospitals in Hong Kong and one 
military hospital in China. Two of these studies tested the safety and efficacy of 
lithium in SCI patients, and three studies an experimental combination therapy of 
umbilical cord blood (UCB) mononuclear cells, lithium, and methylprednisolone. A 
Phase III trial incorporating more hospitals (including those in Taiwan) is being 
planned in 2014. The SCI Net USA has not yet conducted clinical trials, but Phase II 
and Phase III studies are in preparation. The UCB stem cells that are used in the trials 
of the Network are sponsored by the US-Taiwanese umbilical cord blood bank 
company Stemcyte. The organization of the trials itself is covered by financial 
resources raised within China and Hong Kong (Rosemann, 2013b).   
The data presented in this article have been gathered during a period of ten 
months of ethnographic fieldwork in Hong Kong, Taiwan, and mainland China, 
between April 2010 and April 2011. The formation of the China SCI Net was 
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analyzed against the wider background of clinical stem cell research and applications 
in these regions, particularly in mainland China (Rosemann, 2011, 2013a). The data 
generated in Taiwan are not included in this article because the main activities of the 
Network during the fieldwork stage took place in Hong Kong and China.  
Several methods of data collection were employed during the research 
process. Open-ended, in-depth interviews were conducted with twenty-eight people 
affiliated to the China SCI Net. These included senior executives, principal 
investigators, clinical researchers, and fundraisers, from ten participating hospitals 
and institutes. These interviews were either tape-recorded and transcribed verbatim, 
or recorded by hand during the interview process. All interviewees were explained the 
purposes of the research, and verbal consent to use interview data for academic 
publications was obtained. Documentary research was conducted using text sources 
provided by people from the Network and from the Internet. These documentary 
sources included scientific papers, opinion pieces, newspaper articles, blog 
contributions of researchers, as well as video-documentation of panel discussions and 
presentations during international symposia organized by the China SCI Net. The 
article draws, furthermore, on observations of scientific conferences, expert meetings, 
and visits to hospitals and research centers. The research that underlies this article has 
received ethical review and approval by the University of Sussex.  
Data analysis was ongoing during fieldwork and in the months thereafter. 
Everyday work practices and organizational procedures were examined in relation to 
the institutional and regulatory orders, in whose context these activities took place 
(Smith 2005). By repeatedly reading and coding interview transcripts, field notes and 
relevant text sources I identified, in a first step, the different stages and procedures 
through which standardized research protocols were developed and implemented in 
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the context of the China SCI Net. Then, in a second step I explored the challenges to 
standardization, and the ways in which these difficulties were interpreted and tried to 
be solved. This second line of analysis was based on the constant comparative method 
(Boeije 2002) and triangulation of data from different sources. In a third step I 
examined the similarities and differences between locally evolved and internationally-
recognized experimental clinical practices in hospitals that take part in international 
stem cell trials. In order to discern the specific forms of value creation that emerged 
from these distinct experimental practices, I relied on the investigation of interview 
data and the analysis of hospital websites, commonentary and opinion pieces, as well 
as advertising materials from the Internet.   
 
Intercontinental stem cell trials and the role of scientific self-governance 
 
What we are trying to do is to bring the international standards of clinical trials to 
China. [W]hat we are doing is to bring in the concept of using all the modern standards 
on how to run a clinical [stem cell] trial, as it is recognized in the West, in the current 
time. All the conceptions of leading this network … evolve around that concept. […] 
First of all we had to promote the interest […] to bring in experts from around mainland 
China, Hong Kong, Taiwan […], to provide a platform. And the second level is, we 
would then bring in the knowledge as to how a clinical trial should be run, in an 
internationally recognized manner.  
(Prof Kwok-Fai So, Co-Director of China SCI Net) i 
 
Multicountry clinical trial collaborations, such as the China SCI Net, represent the 
first projects in regenerative stem cell medicine where such processes of cross-border 
standardization can be observed.  
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Standards, as Brunsson and Jakobsson have pointed out, coordinate 
assemblages of things and people into new configurations, and in doing so transform 
existing practices, institutional arrangements, and related social orders (2000: 49). In 
the case of the China SCI Net this reconfiguration of things, practices, arrangements, 
and people is based on an interconnected sequence of organizational procedures, 
educational, and training activities, and the employment of a tailor-made monitoring 
and control system. In the absence of a harmonized global governance framework for 
clinical stem cell research, these efforts rest primarily on extensive forms of 
transnational scientific self-governance. Such project-internal forms of self-
governance are strategic efforts to navigate through a diverse and internationally 
nonharmonized regulatory environment; the aim is to create compliance with the 
divergent requirements of drug regulatory authorities and related processes of peer 
review in multiple countries (cf. Wahlberg, et al., 2013). A focus on these processes 
of scientific self-governance, provides important insights into the ways in which 
scientists try to balance out regulatory disparities between regions and institutions, 
compensating for regulatory gaps, and creating congruence with the auditing demands 
of diverging regulatory and political systems (Sariola, & Simpson, 2011; Sleeboom-
Faulkner, 2013).  
Indeed, if data from clinical trials that are conducted in one country are to be 
used for investigational new drug applications in other countries (as in case of the 
China SCI Net, where data from Phase I/II trials conducted in Hong Kong and 
mainland China are to be used to obtain approval for Phase II and III trials in the 
USA, Taiwan, and Hong Kong), the basic regulatory requirements of these countries’ 
drug regulatory authorities must be met. Clinical trials conducted by the Network in 
mainland China thus must be congruent with the methodological standards required 
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for the approval of later-stage (or parallel) trials, by the health authorities in Hong 
Kong, Taiwan, and the USA. I will now turn to the ways in which such transnational 
forms of scientific self-governance are enacted, and how standardization across 
involved institutions is achieved. Three central aspects shall be highlighted in this 
respect: selection, restructuring, and the forestalling of regulatory gaps. 
 
Selection 
 
Selection of the hospitals destined to take part in the Network’s clinical trials is an 
ongoing process. This means that only some of the twenty-five hospitals that initially 
agreed to join the China SCI Net will ultimately participate in the organization’s 
clinical trials. Selection depends, in essence, on the ability of affiliated centers to 
provide evidence that the standards and criteria required for participation in 
internationally recognized (multicenter) clinical trials can be met. A combination of 
external and internal assessment parameters is handled in this respect. External 
assessment parameters refer to outward qualification criteria of associated hospitals. 
These include the Chinese good clinical practice (GCP) certification (i.e., the 
recognition of hospitals as certified clinical trial units, following a qualification 
procedure under the National Health and Family Planning Commission [NHFPC; the 
former Ministry of Health]).ii They include, furthermore, the availability of good 
laboratory practice (GLP) accredited laboratory facilities.iii Internal assessment 
parameters refer to criteria that are imposed on affiliated hospitals by the Network 
itself. These internal qualification criteria can be divided into “performance-based” 
and “organizational” parameters. Organizational criteria cover aspects such as checks 
of hospital internal institutional review board (IRB) approval procedures, the 
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availability of the necessary technical instruments, adequate specialist staff, sufficient 
hospital beds, insurance protection for patients, and adherence to other technical and 
clinical conditions that are contractually defined between the China SCI Net’s 
headquarter and affiliated hospitals. Performance-based assessment criteria have been 
exerted first in the context of the Network’s observational clinical study that was 
conducted in twenty-two hospitals between 2005 and 2008, but have been applied in 
all further trials that the organization has conducted since then. Performance-based 
criteria focus, above all, on the compliance (of each participating hospital) to a 
clinical trial’s protocol, which prescribes the exact clinical, methodological, technical, 
and organizational procedures of a study. The monitoring of protocol compliance 
involves the observation of the correct handling of inclusion and exclusion criteria, 
the conduct of physiological examinations and follow-up investigations, the accurate 
completion of data sheets, and informed consent procedures. These monitoring tasks 
are done from the Network’s headquarters in Hong Kong, which is staffed by the 
organization’s Vice-President Dr. Wendy Cheng, as well as a full-time GCP monitor, 
and a biostatistician. The headquarters operates under the supervision of the 
Network’s board of directors. The Hong Kong office is the nerve center of the China 
SCI Net. All operations of the organization, as well as communication with affiliated 
hospitals, are coordinated from here. In addition to arranging the logistics of the 
Network’s clinical trials, and the monitoring of the activities and performance of 
participating hospitals, the headquarters also plays a central role in the restructuring of 
institutional arrangements and practices in associated centers.  
 
Restructuring 
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The formation of a standardized multi-enter clinical trial infrastructure that operates 
according to internationally recognized principles requires significant adjustments of 
local clinical research practices and conditions in Network-affiliated hospitals. These 
changes were achieved by an intensive training program and the implementation of 
performance-based assessment procedures, through which required institutional 
adjustments could be monitored, and if necessarycorrected. Training for staff 
members of the relevant departments in the twenty-five associated research hospitals 
began in 2005, with three to four meetings per year until 2009. A first target was the 
standardization of neurological examination procedures to ensure valid and replicable 
assessment of the injury grade of spinal cord injury patients on the trial.  
 
When we first came here, the neurological assessment of spinal cord injury – 
almost everywhere – was completely haphazard. It ranged from, eh, you know 
… you take a pin, you put it here, you touch a patient, ask “Can you feel it?” 
There was no discipline … no common languages, no common neurological 
assessment of the patients.iv 
 
Standardization of neurological assessment was the first in a long list of 
methodological, clinical, and organizational issues that were addressed. Training 
addressed aspects of clinical trial design, such as protocol development, quality 
assurance measures, the reliable use of outcome measures, long-term follow-up of 
patients, and the ethical and legal issues of clinical trials, as well as requirements by 
foreign drug regulatory authorities and international journals. In its training program, 
the China SCI Net did not work with an examination system. Instead, new contents 
and practices were transmitted through demonstrations and educational materials, and 
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compliance to newly introduced standards, protocols, and standardized procedures 
was then tested in practice.    
A crucial endeavor in this respect was the organization of the observational 
(i.e., non-interventional) trial CN100, a multicenter study that was conducted in 
twenty-two hospitals in mainland China, Hong Kong, and Taiwan. The purpose of 
this study was to collect long-term data from 600 chronic and acute spinal cord injury 
patients, in accordance with international recruitment and measurement protocols. In 
addition to the scientific value of this studywhich was the first longitudinal 
observational study of chronic and acute spinal cord injury patients in Chinait 
fulfilled a central function for the Network: to serve as a test trial of the ability of 
affiliated centers to recruit patients, to conduct standardized neurological assessments 
[based on the ASIA scheme, developed by the ISCS], to carry out long-term follow-
ups, and to document data and data-collection procedures in the 
prescribedstandardizedfashion. This study helped in identifying various 
challenges:  
 
The first trial we held was an observational trial. To show that the hospitals can 
deliver the data … Now this study revealed a lot of problems I actually had 
heard about, but never really encountered, until to this point. The number one 
problem in China is really to get patients to come back [for follow-up 
investigations]. … But we [also] observed data that just could not have been. 
You know – patient data would be the same, over the whole year period. 
Suggesting that someone had examined the patients very carefully … It 
became very clear to us that we need to have very good controls of the 
protocol.v 
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Due to these problems, instead of the intended 600 patients only 386 patient profiles 
were completed in this firstentirely observationalstudy. These insights into local 
conditions and related challenges resulted in the wide-ranging restructuring of the 
control and monitoring structures through which the Network operated, such as the 
introduction of a supervisor–principal investigator double-signing system. With this 
system, each doctor or nurse involved in examination of patients has to “sign off” the 
data collection sheet with his or her supervisor and the principal investigator in the 
institute. Documentation protocols, moreover, were changed from paper to a 
computerized web-based system for data entry, in order to enhance data insertion and 
data analysis, and to permit continuous checks by the headquarters in Hong Kong. 
Identification of challenges in this observational study gave rise, too, to adjustments 
of training procedures, as well as the decision to work with a Contract Research 
Organization (CRO) during the forthcoming Phase III trial.vi  
 
The forestalling of regulatory gaps 
 
The selection of suitable hospitals, and adjustments of local clinical research practices 
and conditions, aim at the consistent implementation of fully standardized clinical 
research protocols. In contrast to multicenter clinical trials that are conducted in a 
single country, the project-internal forms of self-regulation, capacity building, and 
institutional restructuration that have been described constitute a long-term strategic 
endeavor to create congruence with the auditing demands of widely varying 
regulatory and legal systems. At the time of writing, the clinical trials of the Network 
had been approved exclusively by the regulatory authorities in Hong Kong and 
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mainland China, but the data from these trials will be used for investigational new 
drug applications (INDs) in the USA. This required an enduring anticipatory 
engagement with the review and approval criteria of the US Food and Drug 
Administration (FDA) with respect to the “acceptance of foreign clinical studies not 
conducted under an investigational new drug application (non-IND foreign clinical 
studies)” (Fink, 2008). This constant need for forms of “anticipatory audit” (Strathern, 
2008: 308) requires the identification and forestalling of regulatory gaps between 
national jurisdictions from an early stage of the clinical translation process. A brief 
example will serve to illustrate this point. At the time of writing, the Health 
Department of the Army General Logistics Department in China (the regulatory 
agency that approved the China SCI Net’s clinical studies in mainland China) did not 
mandatorily require that clinical studies should be conducted in compliance with ICH-
GCP standards. Nor did it require the clinical trials to be conducted exclusively in 
hospitals certified by the Chinese MOH, as officially recognized clinical trial units. 
However, the US FDA’s list of requirements for the acceptance of “non-IND foreign 
trials” (in the context of IND applications at the US FDA) states that “accordance 
with good clinical practice (GCP), including review and approval by an independent 
ethics committee (IEC)” is obligatory (Federal Register, 2008). In order to preempt 
any difficulty arising from these discrepancies, the China SCI Net tried to forestall 
regulatory gaps from the outset, and ensured their clinical trial protocols were fully 
GCP compliant and only MOH-certified hospitals were selected. Moreover, in 
addition to approval by the Army General Logistics Department in Beijing, ethics 
committee review was also sought by Western IRB, a for-profit IRB in the USA with 
close ties to the US FDA.  
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The emergence of new style of practice  
 
In their analysis of the development of cancer clinical trials in the USA, Keating and 
Cambrosio described this process as the establishment of a “new style of biomedical 
practice” (2011: 3). This new style of practice encompassed the organization of 
clinical trials within a cooperative group system, and the development of most of the 
now commonly used methodological components of multicenter clinical trials. The 
work in cooperative groups evolved gradually since the mid-1950s, on the initiative of 
the U.S. National Cancer Institute (NCI). Specializing in specific forms of cancer, 
these groups involved hospitals, academic centers, and government departments, and 
constituted steady platforms for the design of new research and the conduct of clinical 
trials (ibid.: 86). These cooperative oncology groups soon expanded into national-
level organizations with their own centralized institutions that were responsible for 
the coordination of all successive steps of the clinical translation process. In this 
system, decisions regarding the design of clinical trial protocols and the organization, 
execution, approval and statistical data analysis of clinical trials were no longer taken 
by individual investigators, but in a collectivist process by the cooperative’s 
committees and its centralized administrational units (ibid.: 25−6). 
In the China SCI Net we see processes of collectivization and standardization 
emerging that in several respects are similar to the cooperative clinical trial system 
described by Keating and Cambrosio. In the mid-2000s, at the time the China SCI Net 
was launched, the organization of an academia-based multicenter clinical trial 
infrastructure was still a radical novelty in the stem cell field in China. While 
standardized multicenter drug trials had been conducted in China by multinational 
pharmaceutical companies since the early 1990s (Cooper, 2006), clinical 
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experimentations with stem cells were for many years based largely on an “the-art-of-
medicine” approach, in which tailor-made experimental treatments were designed for 
the idiosyncratic needs and disease conditions of individual patients (Rosemann, 
2013a). Against this background, the formation of an internationally operating 
multicenter clinical trial infrastructure that would allow for the testing and 
marketization of stem cell-based medicinal products, not only in mainland China, but 
also in Hong Kong, Taiwan, and at a later point in the USA, was a radical and 
fundamentally new concept.  
Similar to the cooperative oncology research groups described by Keating and 
Cambrosio, the China SCI Net established a centralized administrative structure, in 
which the monitoring of clinical and data collection procedures, statistical analysis, 
and decisions regarding protocol development and the selection of candidate therapies 
for future clinical trials were collectivized. These tasks were performed by specialist 
staff in Hong Kong, and by expert committees that comprised researchers from 
affiliated institutions and independent experts, from mainland China, Hong Kong and 
the USA. Together with the installing of a standardized research methodology that is 
suitable for the conduct of multicenter clinical trials, these changes have established a 
new style of clinical research practice in Network-affiliated hospitals that is based on 
extensive adjustments of local research procedures. As with the cooperative oncology 
groups in the USA, the China SCI Net functions as an “epistemic organization” in 
which clinical trials are not isolated events, but elements of an “integrated, open 
ended set of activities that stretch back and force in time” (Keating, & Cambrosio, 
2011: 24). The design of new trials is built on previous trials, and the use of 
standardized methodological protocols allow for systematic comparison and meta-
reviews of findings from multiple studies over time.  
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A fundamental difference with the cooperative group system described by 
Cambrosio and Keating is, however, that affiliated investigators of the China SCI Net 
are entirely free to conduct their own clinical studies, exterior to the organizational 
framework of the Network. A central reason for this is, of course, that the China SCI 
Net is an independent research groups that is neither a national-level organization nor 
structured around a government research institution (such as the NCI, which is at the 
center of the cooperative oncology group system in the USA). Thus, in contrast to the 
cooperative groups in the USA, where members are prevented from initiating 
investigator-initiated collaborations outside of the cooperative system, researchers 
from the China SCI Net can independently pursue their own projects. Membership is 
solely delimited to participation in the trials that the Network organizes. It does not 
impinge on, or restrict, any other activities that Network-affiliated investigators 
conduct in their own departments or institutions. 
Indeed, as I will now show, exterior to the institutional framework of the 
China SCI Net a stream of highly divergent forms of clinical experimentation has 
been employed in recent years. In a hospital in North China, for example, a doctor 
had offered experimental for-profit therapies with olfactory ensheathing cells in 
hundreds of SCI patients. In other hospitals I visited, various non-controlled clinical 
pilot studies with stem cells were conducted, but none of these studies could be 
published in international journals because the methodology of these studies was 
described as insufficient (Young, 2008). In a clinic in South China, on the other hand, 
participation in rigorous RCTs (as part of the activities of the China SCI Net) 
coexisted with the conduct of less systematic clinical studies, in which experimental 
treatments with various cell types, and other experimental treatment approaches, were 
offered to patients, on a pay-to-participate schema. Apparently, these studies did not 
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entirely conform to international EBM clinical research standards. Attempts to 
publish results from these studies in internationally recognized academic journals 
repeatedly failed (ibid.).  
However, in the context of my interviews with clinical researchers affiliated to 
the China SCI Net, it became clear, that a shift toward the employment of more 
systematic clinical studies was gradually taking shape in Network-affiliated hospitals. 
Most of the Principal Investigators with whom I spoke mentioned plans for trials with 
the use of control groups, and more rigidly handled inclusion criteria.vii One of the 
hospitals I visited was in the process of planning a larger Phase III trial and had set up 
a province-level multicenter clinical network to this end.viii These changes can, with 
high likelihood, be related to the extensive training and education program introduced 
by the China SCI Net.   
 
Standardization as situation-specific achievement 
 
Standards, as pointed out by sociologists Timmermans and Epstein, construct a state 
of stability and order across diversity and plural possibilities (2010: 71). As 
underlying scripts of rules, procedures and values, standards produce uniformities in 
behavioral practices, sociotechnical arrangements and knowledge (Timmermans, & 
Berg, 1997). For international scientific projects, standardization constitutes a crucial 
methodological requirement, because it enables systematized replication, assessment 
and validation of research findings across institutions, scientific communities and 
time. Barry (2006) has in this respect spoken of the creation of “technological zones,” 
which he has defined as “space[s] within which differences between technical 
practices, procedures and forms have been reduced, or common standards have been 
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established” (ibid.: 239). While Barry recognizes that the establishment of such 
technological zones is contested and characterized by variation and changes over 
time, the concept implies that a shared standard has become the guiding norm, and is 
resulting in a reduction of differences between conflicting socio-technological 
practices. 
In emerging technology fields, such as regenerative stem cell medicine, where 
state regulations are still evolvingand internationally harmonized regulatory 
frameworks are not yet in place, a more complex situation exists however. The case 
study of the China SCI Net indicates in this respect, that due to the high level of 
regulatory diversity in the stem cell field across (and also within) countries, the 
enactment of internationally recognized research standards in multi-country stem cell 
trials is a highly situation-specific achievement. Internationally approved clinical 
research protocols are established against a background of geographic, institutional, 
epistemic-cultural and regulatory heterogeneity, and implemented exclusively in the 
situational context of the clinical trials that the Network organizes. As shown in the 
previous section, outside of the activities of the China SCI Net, we see that locally 
evolved and newly adopted (i.e. internationally accepted) forms of experimental 
clinical research practices exist side by side with each other, often in the same 
medical institutions. If we conceive of the China SCI Net as the formation of a 
technological zone, in the sense Barry uses the term, it becomes clear that the 
existence of such zones can be highly temporary, and depends upon its activation in 
specific situational contexts. Standardized methodological norms and work 
arrangements across Network-affiliated hospitals are activated exclusively in the 
context of the Network’s clinical trials; outside the context of these trials, 
heterogeneous clinical practices continue to exist.  
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This situation-specific character of transnational technological zones, in which 
established standards can lay dormant for a while, and switched on and off in relation 
to contextual demands, has not yet been systematically explored in the literature. The 
case study of the China SCI Net indicates in this respect, that in medical institutions 
that take part in such evolving transnational infrastructures, the adoption of 
homogenized clinical research standards may only be temporary and bound to 
participation in specific projects. Forms of clinical experimentation that have 
historically evolved in local institutions and more recently adopted (i.e. 
internationally recognized) clinical research practices, continue to exist side by side 
with each other. Researchers switch back and forth between these divergent schemas, 
depending on the purposes of their research, the partners they work with, the 
geographic scale of research projects, the targeted territorial scope of marketization, 
and the contrasting demands for regulatory review and approval that result from these 
differences. This situation differs fundamentally from the oncology research 
cooperatives described by Keating and Cambrosio (2011), where the adoption of a 
centrally defined set of research standards has become a permanent and obligatory 
requirement, and possibilities for clinical experimentation outside of the cooperative 
structure have become impossible.  
 
The continuance of localized forms of value production 
 
A key point is that the coexistence of distinct modes of clinical translation allows also 
for the production of multiple forms of economic value, at the level of local medical 
institutions. Localized forms of value creation, which would not be acceptable to drug 
regulatory agencies overseas, continue to exist – aside to participation in the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
internationally approved, multi-country clinical research trials organized by the China 
SCI Net. As mentioned above, in a clinic in South China experimental treatments with 
various cell types were offered to patients in the context of clinical pilot studies, 
exterior to the hospital’s involvement in the Network’s stem cell trials. These 
experimental treatments have been offered to patients on a pay-to-participate schema. 
The intensive rehabilitation program that is now part of the China SCI Net’s clinical 
trial protocols, was also developed in this hospital. While the efficacy of this 
experimental rehabilitation program shall be determined in the context of the 
network’s clinical trials in the future, it is offered since 2012 in a private hospital in 
China on a for-profit basis, and advertised to domestic patients and to spinal cord 
injury patients from overseas. Another example that reflects the local forms of 
economic value production that have emerged in some of the institutions affiliated to 
the China SCI Net, are the experimental therapies of a clinical researcher from North 
China. This physician has offered experimental cell treatments to reportedly several 
thousands of patients, from more than eighty countries’ during the last years (IANR 
2010). This researcher did not, however, actively participate in the China SCI Net’s 
clinical trials, but due to his long-standing experience he played an important advisory 
role in the selection and development of the surgical and cell transplantation 
procedures that were used in the Network’s clinical trials. 
The existence of such localized forms of value creation, that have emerged 
outside of the requirements of international standard regimens, aside to participation 
in internationally approved trials can also be observed in other international research 
projects in China. Let me illustrate this with the example of a collaboration between 
Neuralstem, a biotech company from the USA that develops stem cell-based therapies 
for neurodegenerative disorders, and a large military hospital in Beijing. Neuralstem 
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has received approval from the US FDA for Phase I and II stem cell trials for 
amyotrophic lateral sclerosis (ALS). These studies have been conducted in the USA 
since 2011. In December 2013 the company launched also a Phase I/II trial for the 
treatment of ischemic stroke in China. The trial is carried out in a well-known military 
hospital for brain disorders in Beijing. According to Richard Garr, the CEO of 
Neuralstem, the protocol of the China trial has been developed for use in the USA at a 
later point. It is performed in line with GCP standards, and based on the quality 
controls and protocols for expansion that are required by the US FDA (Ellis 2014). Of 
interest is that, aside to taking part in this high-profile international clinical research 
project, the hospital in Beijing has for many years offered experimental for-profit 
stem cell treatments, through its Stem Cell Therapy Centre. On its website the center 
advertises experimental treatments for a broad range of neurodegenerative disorders, 
that range from stroke, to cerebral palsy, to Parkinson’s disease, Alzheimer’s disease, 
spinal cord injury, and others.ix While reportedly 300 patients from various countries 
had been treated until 2011, in recent years the hospital seems to have focused in 
particular on the Chinese market for the treatment of cerebral palsy. These 
experimental for-profit stem cell treatments are widely advertized, both on the 
hospital’s Chinese website, and on external Chinese language websites.x  
These findings indicate, that the integration of local knowledge institutions 
into a global research economy does not unavoidably result in the shutting down of 
localized forms of value production, as recently argued by sociologist Kean Birch 
(2012). As Birch (2012) has pointed out, the incorporation of local institutions and 
locally derived inventions into a standardized global knowledge economy, is 
intrinsically accompanied by the closing of local market opportunities and knowledge 
exchanges. Localized forms of exchange and profit generation, which have emerged 
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in the original context of knowledge production, are terminated, through the 
mandatory use of international standards, unified research methodologies, and the 
application of legal instruments such as international intellectual property rights (IPR) 
and global trade rules (ibid.: 190). While Birch’s argument may be valid in more 
established research fields in the biosciences where large-scale transnational 
corporations play a central role, and in countries in which comprehensive regulatory 
arrangements are in place, in emerging fields of medicine research, a more diversified 
situation exists.  
The example of the China SCI Net has shown in this respect, that localized 
forms of value creation in medical institutions, that do not conform to the 
requirements of international scientific standard regimens, continue to exist – aside to 
participation in internationally approved, multi-country clinical research projects. But 
the coexistence of processes of clinical translation through the conduct of systematic 
forms of clinical trials, and the provision of experimental for-profit stem cell 
therapies, have also been documented in other medical institutions and companies in 
China (Chen, 2009; Song, 2011), as well as India (Sleeboom-Faulkner, & Patra 2011). 
As recently suggested by McMahon (2014), the provision of unproven stem cell 
intervention has itself developed into a global industry that is now provided to tens of 
thousands of patients and generate significant economic revenues.  
Here, two issues deserve to be mentioned. The first is that participation of 
hospitals in international clinical research projects may increase the level of 
legitimacy for the provision of locally evolved experimental therapies. This, in turn, is 
likely to maximize local forms of value creation, also if these treatments have not 
been developed in accordance with internationally recognized clinical research 
standards. The second point is that the integration of hospitals into a multi-country 
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clinical trial infrastructure may foster the adoption of an evidence-based medicine 
(EBM) research culture – also in the context of local research projects. In the case of 
the China SCI Net, for example, several of the investigators with whom I spoke had 
started to conduct randomized controlled trials, including domestic multi-center 
studies, independently from the China SCI Net. These researchers reported that, in the 
field of spinal cord injury research, the shift toward more systematic clinical trials 
was driven in particular by discontent with the widespread availability of unproven 
for-profit stem cell therapies in China, and related concerns for patients. 
 
Local value and the violation of property rights  
 
A point that is thematically related to the argument of this article, albeit not central to 
it, is that possibilities for the continuation of localized forms of value creation are also 
linked to cross-national differences in the enforcement of intellectual property rights 
(IPR). In India, China and other rapidly developing countries the protection and 
enforcement of property rights is often problematic. In China and India, for example, 
a longstanding record of IPR infringements exists, including in the production of 
medicines (Brhlikova, et al., 2011; Mackay, & Liang, 2011). IPR infringements are 
also an issue in the field of regenerative stem cell medicine. For instance, the 
umbilical cord blood mononuclear cell / Lithium combination that is tested by the 
China SCI Net (and which has been patented by Stemcyte, the sponsor of the UCB 
cells) was experimentally applied by a clinical researcher in India even before the 
initial Phase I trial of the China SCI Net in Hong Kong had started, apparently 
without any legal consequences.xi Similar forms of IPR infringements were also 
expected in China, provided the tested treatment is proved to be safe and efficient. 
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Researchers of the China SCI Net stated, that legal prosecution of hospitals in China 
that would offer the combination of Lithium and UCB cells from somewhere other 
than Stemcyte is very unlikely. These researchers expected, that alternative UCB 
products would soon surface in the Chinese market (Rosemann, 2013b). For a 
theorization of processes of value creation in the global bioeconomy, the implicit 
acceptance of property right violations is important, because it refers to the profit 
potential of informal and illegal economic activities in the biotech sector. In this 
article, though, I have pointed to something else. I have shown that in emerging fields 
of medicine research, that are regulated in highly divergent ways across geographical 
regions, locally evolved clinical research and for-profit practices can continue to 
exist–––parallel to the integration of local institutions into a standardized global 
research economy. In contrast to profits generated from IPR infringements, however, 
these localized forms of value creation usually do not take place outside of existing 
legal structures, and could not be prosecuted by international law.   
 
 
 
Conclusions  
 
This paper has illustrated that the heterogeneity of regulation, clinical research 
methodologies, and forms of commercialization that can be observed in the clinical 
stem cell field at a global level poses significant challenges to the organization of 
intercontinental clinical stem cell research projects. It has become clear, that the 
establishment of standardized clinical research practices across this level of diversity, 
is a highly situation-specific achievement. Internationally acceptable clinical research 
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practices exist alongside a broad range of locally evolved forms of clinical 
experimentation, often in the same medical institution. As I have shown, this 
coexistence of divergent socio-epistemic practices has enabled also the generation of 
multiple forms of economic value. I have suggested in this regard that – in contrast to 
a recent argument of Birch – the integration of local institutions into the global 
bioeconomy does not necessarily result in the shutting down of localized forms of 
value creation. The findings of this paper indicate, that the high level of generalization 
that underlies Birch’s analysis of present-day processes of value creation in the global 
bioeconomy, leaves out some fundamental issues.  
A first point is that in emerging fields of medicine research, such as stem cell 
research, the key actors are often not transnational corporations, as stated by Birch. In 
the field of regenerative stem cell medicine, large-scale pharmaceutical corporations 
have for many years been hesitant to invest. The main advances, and forms of profit 
making that have evolved in recent years, were made by small to mid-size biotech 
companies, usually in conjunction with academic institutions. In countries where 
clinical stem cell applications have been regulated at a low level, moreover, lucrative 
business opportunities have been exploited by private clinics, local investors, and 
even individual physicians (Rosemann 2013a; McMahon 2014). This suggests, that – 
in order to get a more nuanced picture of contemporary processes of value production 
in the biomedical sciences – it is necessary to depart from a more nuanced analysis of 
the different types of stakeholders that interact in the context of specific subfields of 
the biomedical sciences. The second point concerns the need to take into account 
variation in terms of geographic and regulatory location. In both, China and India 
state agencies have taken for many years now a very reluctant position in adopting 
stringent regulatory frameworks for clinical stem cell applications, and to harmonize 
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regulations with those issued in the USA and European Union. In my fieldwork in 
China in 2009 and 2010 various policy makers expressed fears that the adoption of 
procedures as handled by the US Food and Drug Administration, might suffocate 
local innovation and market opportunities in the stem cell field in China. Minimal 
regulatory intervention, from this perspective, may form a conscious political strategy 
to endorse localized forms of value creation, at least up to the point at which more 
profitable, exportable products have been developed (Sleeboom-Faulkner 2014). 
These geographically-based differences in policy positions, and their implications for 
processes of innovation and market exchange, must be clearly understood in a theory 
of value creation of the global bioeconomy. State agencies, as this example suggests, 
are not always complicit in adopting (or enforcing) internationally harmonized 
regulatory frameworks that prioritize global forms of exchange, above policy options 
that prioritize more localized forms of market activity. Third, geographic variation in 
the enforcement of international IPR agreements is another crucial factor that must be 
taken into account to fully comprehend the divergent ways in which economic value 
is created in the global biomedical economy. The implicit acceptance of property 
rights infringements in many countries refers also to the huge financial potential that 
the production of counterfeit medicines, and in the future probably soon - alternative 
stem cell products – generate.  
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i Interview Kwok-Fai So, Hong Kong, January 7, 2011. 
ii Interview Wise Young, Hong Kong, June 24, 2010. 
iii Interview Kent Tsang, Hong Kong, January 7, 2011. 
iv Interview Wise Young, Hong Kong, June 24, 2010. 
v Same source as in note iv. 
vi Same source as in note iv. 
vii Only some of these trials were with cells or stem cells. Others were surgical trials, comparing 
different techniques and operation times. 
viii Interview Nr. 20, senior researcher, South East China, September 7, 2010. 
ix
 Website of Stem Cell Therapy Centre, Bayi Hospital; URL: http://www.81scc.com/en/zxjs.asp 
x The Chinese language website of the Bayi Hospital on wich these experimental stem cell treatments 
are advertised can be found here: URL:  http://www.zznews.cn/yst/jdft/920140708281730.html  
This and other websites on which these therapies are advertised, have an interactive live-chat-
function, that allows interested patients to get information on the treatment from hospital staff. 
xi
 This was reported by the researcher who conducted these experiments, at a conference in Taiwan in 
April 2010. 
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Highlights  
 
- The paper explores standardization and self-governance in global stem 
cell trials 
- Standardization in stem cell trials is a highly situation-specific 
achievement 
- Locally evolved and international research standards coexist in the same 
hospitals 
- This coexistence of diverging standards enables multiple forms of profit 
production 
- The adoption of international standards does not stop local forms of value 
creation 
 
 
